Noon Announcement: Fusenmei plans to reduce rent and service fees for self-operated shopping malls

time:2023-03-22 01:29:09source:chakarski.com author:Stock market
Noon Announcement: Fusenmei plans to reduce rent and service fees for self-operated shopping malls

e company news, ① Degute: Wei Feng and Shanghai Qingwang Venture Capital Partnership (Limited Partnership), who hold a total of 3.75% of the company's shares, plan to reduce their holdings of the company's shares by a total of no more than 5.625 million shares ( 3.75% of the company's total share capital). ② Chengde Lulu: As of September 16, the company’s shares repurchased through centralized bidding reached 2.07% of the total share capital, with a total payment of about 187 million yuan. ③ Fusenmei: In the past two months, the high temperature power cuts and the new crown epidemic in the Chengdu area have had a certain impact on the normal operation of physical stores/markets in the region. The company plans to reduce or exempt the rents of shops in the respective shopping malls/market merchants of Fusenmei Chengdu. and service fee. This reduction and exemption arrangement involves the company's operating income (total rent and service fees) in 2022 not exceeding 100 million yuan, accounting for no more than 6.51% of the company's operating income in 2021; the impact on the company's net profit attributable to the parent in 2022 is about 70 million yuan , accounting for about 7.62% of the net profit attributable to the parent in 2021. ④Longjin Pharmaceutical: Yunnan Zhongke Longjin Biotechnology Co., Ltd., a holding subsidiary, obtained the approval notice for drug clinical trials for "ZKLJ02 for injection". The drug is suitable for acute ischemic stroke and improves neurological deficits. ⑤Poinsettia: The wholly-owned subsidiary has obtained the approval notice for the supplementary application of ambroxol hydrochloride drops, which indicates that the company has the qualification to sell drugs of this specification in the domestic market, which will further enrich the pipeline and categories of the company's children's drug products.
Related content